The Comparison of The Efficacy and Safety of Original and Biosimilar Filgrastim in Prevention of Chemotherapy-Induced Neutropenia in Children with Cancer

Buyukavci M., KESKİN YILDIRIM Z.

EURASIAN JOURNAL OF MEDICINE, vol.51, no.2, pp.112-115, 2019 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 51 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.5152/eurasianjmed.2018.18030
  • Journal Name: EURASIAN JOURNAL OF MEDICINE
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.112-115
  • Ataturk University Affiliated: Yes

Abstract

Objective: In adults and children, the duration of chemotherapy-induced neutropenia and associated complications has decreased because of the prophylactic use of granulocyte colony-stimulating factors (G-CSFs). Biosimilar G-CSFs can play an important role in reducing treatment costs in daily practice. However, some concerns regarding the efficacy and safety of new biosimilar products exist among clinicians. This study compared the efficacy and safety of original and biosimilar filgrastims for the prophylaxis of chemotherapy-induced neutropenia in children.